In:
Journal of Biomaterials and Tissue Engineering, American Scientific Publishers, Vol. 12, No. 7 ( 2022-07-01), p. 1417-1422
Abstract:
This study assesses lncRNA-CCAT2’s role in reducing the drug resistance of ovarian cancer cell lines. Cisplatin-resistant SKOV-3/DDP cells were established and assigned into CC group (transfected with lncRNA CCAT2 siRNA-NC) and CA group (transfected with lncRNA CCAT2 siRNA) followed
by analysis of cell proliferation, apoptosis, expression of CCAT2, ERK1/2, Sp1 and relationship between CCAT2 and ERK1/2 and Sp1. CCAT2 expression in SKOV-3/DDP was higher than IOSE80 and SKOV-3 ( P 〈 0.001). ERK1/2 expression in SKOV-3 and SKOV-3/DDP was 0.67±0.09, 1.97±0.40
( t = 14.18, P 〈 0.001). Sp1 level in SKOV-3 and SKOV-3/DDP was 0.49±0.05, 1.07±0.11 ( P = 21.47, P 〈 0.001). Transfection of CCAT2 reduced cell fluorescence activity of ERK1/2 and Sp1 ( P 〈 0.001). Cell proliferation in CC group and CA
group had no difference at 0 h ( P 〉 0.001) and the inhibition of cell proliferation was found at 24 h ( P 〈 0.001). CC group (5.13±0.51) had lower cell apoptosis rate than CA group (20.52±2.24) ( t = 29.96, P 〈 0.001) but higher ERK1/2 and Sp1
protein level CC group than CA group ( P 〈 0.001). In conclusion, transfection of lncRNA-CCAT2 inhibits SKOV-3/DDP proliferation by targeting ERK1/2-Sp1 signaling pathway, promotes apoptosis and reduces drug resistance.
Type of Medium:
Online Resource
ISSN:
2157-9083
DOI:
10.1166/jbt.2022.3044
Language:
English
Publisher:
American Scientific Publishers
Publication Date:
2022
Permalink
